CytomX Therapeutics (CTMX) Cash & Equivalents (2014 - 2026)

CytomX Therapeutics (CTMX) has 13 years of Cash & Equivalents data on file, last reported at $28.8 million in Q1 2026.

• Quarterly Cash & Equivalents fell 39.44% year-over-year to $28.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.8 million (down 39.44% YoY) and the FY2025 annual result came in at $12.7 million, down 66.71% from the prior year.
• Cash & Equivalents rose to $28.8 million in Q1 2026, from $12.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $193.6 million in Q4 2022 to a low of $12.7 million in Q4 2025.
• A 5-year average of $62.9 million and a median of $43.2 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents plunged 91.13% — and 2024, when it soared 121.61%.
• Tracing CTMX's Cash & Equivalents over 5 years: stood at $193.6 million in 2022, then sank by 91.13% to $17.2 million in 2023, then soared by 121.61% to $38.1 million in 2024, then slumped by 66.71% to $12.7 million in 2025, then surged by 127.58% to $28.8 million in 2026.
• The last three Cash & Equivalents figures came in at $28.8 million (Q1 2026), $12.7 million (Q4 2025), and $34.2 million (Q3 2025), per Business Quant data.